A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

​ Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Amivantamab; Drug: Lazertinib; Drug: Carboplatin; Drug: Pemetrexed

Sponsors: Janssen Research & Development, LLC

Not yet recruiting Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Amivantamab; Drug: Lazertinib; Drug: Carboplatin; Drug: Pemetrexed
Sponsors: Janssen Research & Development, LLC
Not yet recruiting